In a move that is already sending ripples through the financial and pharmaceutical sectors, global index provider MSCI announced on February 10, 2026, that Samsung Epios Holdings will be newly included in the influential MSCI Korea Index. The decision, revealed during MSCI’s regular February review, comes alongside the inclusion of Hyundai Construction and the removal of three major companies: Coway, Doosan Bobcat, and LG Household & Health Care. This adjustment reduces the number of stocks in the index from 82 to 81, a shift that is expected to have significant ramifications for both investors and the companies involved.
The MSCI Korea Index is considered one of the world’s most influential stock benchmarks, serving as a critical barometer for global institutional investors. According to Seoul Economic TV, inclusion in the index typically triggers inflows of passive capital, as a multitude of investment funds and asset managers track the index composition closely. Conversely, companies that are excluded often experience capital outflows, as funds are forced to rebalance their portfolios in line with the new index makeup.
The latest review and adjustment, which will become effective after market close on February 27, 2026, is part of MSCI’s regular quarterly process. MSCI reviews its indices every February, May, August, and November, basing changes on each company’s market capitalization and free float market cap. As noted by Yonhap Infomax, this systematic approach ensures that the index remains representative of the Korean equity market and responsive to shifts in market dynamics.
For Samsung Epios Holdings, the inclusion marks a dramatic turnaround after a challenging period. Since its spin-off from Samsung Biologics in November 2025, the company had witnessed significant outflows of passive capital. This was largely due to its absence from major indices, which led to a drop in its share price and a foreign investor ownership rate of just 6.09%—barely half that of its former parent, Samsung Biologics. As Pinpoint News reports, the expectation now is that inclusion in the MSCI Korea Index will reverse this trend, attracting fresh capital and providing much-needed stability to the stock.
The mechanics behind the inclusion are as rigorous as they are consequential. MSCI evaluates candidates based on a combination of total and free float-adjusted market capitalization, as well as liquidity ratios. For Samsung Epios Holdings, the key hurdle was the liquidity ratio, with a 25% threshold considered likely for inclusion. Industry analysts, such as Kim Dong-young from Samsung Securities, have noted that, "If the same 25% liquidity ratio applied to Samsung Biologics is used, Samsung Epios Holdings will likely meet the criteria for inclusion."
But what does this mean for Samsung Epios Holdings in practical terms? According to Seoul Economic TV, index inclusion offers more than just a boost to the share price. It also increases the company’s visibility among global investors and makes it easier to attract capital for future ventures, such as rights offerings or strategic investments. This is particularly significant for a company in the biotech sector, where research and development (R&D) costs are notoriously high and access to funding is critical for sustained growth.
Indeed, Samsung Epios Holdings and its operating company, Samsung Biopharmaceuticals (often referred to as Samsung Epios), are already positioning themselves to capitalize on these new opportunities. The company has set out an ambitious plan to expand its biosimilar drug portfolio to 20 products by 2030, aiming to cement its status as a global leader in the rapidly growing biosimilar market. The timing could hardly be better, given the tailwinds coming from the United States.
On February 10, 2026—the same day MSCI announced its review results—the U.S. government officially launched the TrumpRx platform, a federal initiative designed to make prescription drugs more affordable for Americans. As reported by Infomax, TrumpRx is not a direct sales platform but rather a comprehensive price comparison and coupon site, built on the infrastructure of GoodRx. Patients can search for medications, compare prices across pharmacies, and access discounts, including for biosimilars. The White House estimates that the initiative will lower average monthly drug costs by $149 to $350 for Americans, a substantial reduction that is expected to drive demand for lower-cost alternatives like biosimilars.
The U.S. Food and Drug Administration (FDA) is also playing its part, with regulatory adjustments expected by mid-2026 to make it easier for biosimilars to gain approval and be substituted for brand-name drugs at the pharmacy counter. This policy shift is a clear signal that the U.S. government is committed to expanding access to biosimilars, a development that has not gone unnoticed by Samsung Epios Holdings. The company, which already boasts a strong portfolio and distribution network in the U.S., is seen as well-positioned to benefit from these changes.
Industry insiders echo this sentiment. One source told Infomax, "If included in the MSCI index, Samsung Epios Holdings can ascend as a recognized bioenterprise among global investors, accelerating both domestic and international capital attraction." The company’s CEO, Kim Kyung-ah, added during a recent press conference, "The guidelines for biosimilar approval are evolving rapidly, which will expand the market. With our accumulated know-how in maintaining quality and cost competitiveness over the past 14 years, we can sustain our competitive edge."
Samsung Epios Holdings is not resting on its laurels. The company has committed to seeking approval for at least one new clinical trial each year, with a particular focus on antibody-drug conjugates (ADCs) and other cutting-edge therapies. In addition, it is developing seven new biosimilar products targeting blockbuster drugs whose patents are set to expire soon. The company’s strategy is to leverage its R&D capabilities and manufacturing expertise to gain a larger share of the global biosimilar market, which is expected to grow rapidly as healthcare systems seek more affordable treatment options.
Meanwhile, the broader context of the MSCI Korea Index adjustment cannot be ignored. As noted by Yonhap News, the exclusion of Coway, Doosan Bobcat, and LG Household & Health Care reflects the index’s ongoing evolution in response to market trends and capitalization shifts. Each quarterly review brings with it winners and losers, and this time, Samsung Epios Holdings finds itself firmly in the winner’s circle.
The coming weeks will be crucial. With the index rebalancing set to occur after market close on February 27, 2026, all eyes will be on the flow of capital and the performance of the newly included and excluded stocks. For Samsung Epios Holdings, the combination of index inclusion, favorable regulatory changes in the U.S., and a robust product pipeline could mark the beginning of a new era of growth and global recognition.
As the dust settles, one thing is clear: Samsung Epios Holdings has seized a rare double momentum, poised to benefit from both international financial markets and transformative changes in the global pharmaceutical landscape.